Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO

Hunter Smith, chief financial officer of Rhythm Pharmaceuticals (NASDAQ: RYTM), has been appointed interim CEO. He takes the place of Keith Gottesdiener, who announced in January that he planned to leave his executive positions and the board of directors after Rhythm submitted a new drug application for setmelanotide. The application was filed with the FDA earlier this month.